ImmuPharma (LON:IMM) Shares Up 26.9% – Here’s What Happened

ImmuPharma plc (LON:IMM) shares rose 26.9% on Monday . The stock traded as high as GBX 6.54 ($0.09) and last traded at GBX 6.54 ($0.09). Approximately 12,621,519 shares traded hands during mid-day trading, an increase of 77% from the average daily volume of 7,142,729 shares. The stock had previously closed at GBX 5.16 ($0.07).

ImmuPharma Stock Up 18.7%

The stock’s 50 day moving average price is GBX 2.55 and its 200-day moving average price is GBX 2.76. The stock has a market capitalization of £65.96 million, a P/E ratio of -1,483.15 and a beta of 1.53.

ImmuPharma (LON:IMM) last issued its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

ImmuPharma Company Profile

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.